■Company Overview

1. Company history

Care Net ＜2150＞ was established in 1996/7 by the current Chairman of the Board Mr. Motoyasu Ono (Ono Motoyasu) and his colleagues for the purpose of providing medical information for doctors. Initially, the satellite communication broadcast “SKY PER!” “CareNet TV Medical Ch.” was broadcast on, but since 2000, a free membership site “Club Care Net” (now “CareNet.com”) for doctors (including health care workers) using the internet was established, and it was developed into a service for pharmaceutical companies using the internet based on members of the same site.

A marketing research service was launched in 2000/10, and a pharmaceutical sales support service, which is the current main service, began in 2001/11, and business performance expanded thereafter. Since 2014, we have actively promoted partnerships with domestic and foreign companies to strengthen existing services, and we are also focusing on developing and nurturing new services. Furthermore, the marketing research service was transferred to Macromill Care Net Co., Ltd. (part of the shares were sold in the fiscal year ended 2016/12 and became a non-equity law affiliated company), which was established as a joint venture with Macromill ＜3978＞ in 2014/12.

In 2018/5, a business alliance related to venture enterprise investment was concluded with Medical Incubator Japan Co., Ltd., and both companies took the lead in establishing a consortium “SSI (Successful Support for Innovator)” to provide total support for the process from clinical development to sales for pharmaceutical/medical device manufacturers.

Since 2020, subsidiaries for new business development have been established one after another as a growth strategy, and strategic alliances and M&A have been active. In M&A, in addition to acquiring the operation business for the procedure video media “Cancer @魅せ技” from Phase One Co., Ltd. in 2020/4, Admedica Co., Ltd., which operates the comprehensive healthcare media “Doctors Me,” which can be consulted about illness and health, was made a subsidiary in 2021/2. Also, a partnership was concluded in 2020 with the Occupational Medical University Health Management System, Tokio Marine Holdings (8766), and Medical Data Vision (3902) for the development of the health data science business. In November 2021, Healthcare Consulting Co., Ltd. was established through a joint investment with Mr. Kinya Kokubo (Kokubo Kinya), an associate professor at the Nishogakusha University Faculty of International Politics and Economics. We have started a new business with the aim of analyzing all kinds of medical big data such as RWD, QOL/PRO, and PHR data in the healthcare and life science fields and creating strategic evidence. In 2022/8, in order to accelerate DX in the SMO*1 business, the SMO company YMG Support Co., Ltd. was made a subsidiary, Core Human Co., Ltd. (currently CareNet Partners Co., Ltd.), which has a proven track record in the CSO ※2 business (MR business agency), became a subsidiary in October of the same year, and Crais Co., Ltd., a CRO*3 company, was made a subsidiary in December of the same year in order to focus on developing new solutions in clinical trial processes.

*1 SMO: An abbreviation of Site Management Organization (clinical trial facility support organization), indicates an organization that supports clinical trial work of medical institutions by receiving commissions from medical institutions conducting clinical trials in place of pharmaceutical companies that develop new drugs.

*2 CSO: An abbreviation for Contract Sales Organization, indicating a pharmaceutical sales contract organization. Temporary MR is the main service.

*3 CRO: An abbreviation of Contract Research Organization, indicates an enterprise that entrusts and undertakes clinical trial operations (clinical development) carried out by pharmaceutical companies for drug development. In Japanese, it is expressed as a “development contract organization.”

In 2023/11, in order to promote DX for medical institutions and the development of new solutions to solve management issues, we acquired a majority of shares in ValueNext Co., Ltd., a holding company that has two companies under its umbrella: Medical Create Co., Ltd., which engages in cost reduction consulting and in-hospital logistics management system (SPD) implementation support and contract management for medical institutions.

In 2024/2, Klax Co., Ltd. was established as a joint venture with Forest Holdings Co., Ltd., which provides services specializing in engagement (relationship building through dialogue) with physicians. Astem Co., Ltd., a wholly owned subsidiary of Forest Holdings, has the ability to gather information from regional medical institutions and access to facilities as the largest pharmaceutical wholesaler in the Kyushu area, and develops services that support the realization of high-quality engagements by combining the company's medical information content planning and production capabilities with the ability to access doctors through the internet. Furthermore, with the aim of developing a new pharmaceutical business model that consistently provides everything from procurement of new drugs targeting EBP* to efficient clinical trials and sales, we announced capital participation in LinDo Co., Ltd. and the construction of a group alliance. Furthermore, a business partnership agreement on Asian expansion was concluded with Shanghai Medical Rice Information Technology Co., Ltd., which operates one of the largest medical membership platforms in China.

※ EBP: short for Emerging Biopharma. It indicates companies with annual sales of less than 0.5 billion dollars and annual research and development expenses of less than 0.2 billion dollars, and development-specific ventures in the medical industry.

In 2024/3, Mr. Ohno became Chairman of the Board, and Mr. Fujii Katsuhiro (Fujii Katsuhiro) became President and CEO/COO. The management system is not much different from before, but Mr. Ohno is mainly in charge of external negotiations such as overseas projects and M&A.

(Written by FISCO Guest Analyst Ryoji Mogi)